Document is current
Any future updates will be listed below
-
Authors
Minta, K.
Brinkmalm, G.
Janelidze, S.
Sjödin, S.
Portelius, E.
Stomrud, E.
Zetterberg, H.
Blennow, K.
Hansson, O.
Andreasson, U.
-
Funding
Funding for this research was provided by:
Stiftelsen för Gamla Tjänarinnor (-)
Vetenskapsrådet (2018-02532, 2017-00915)
European Research Council
Swedish State Support for Clinical Research (ALFGBG-720931)
Swedish Alzheimer Foundation (AF-742881, -)
Knut och Alice Wallenbergs Stiftelse (-, -)
Hjärnfonden (FO2017-0243)
Marianne and Marcus Wallenberg Foundation
Strategic Research Area Multipark (-)
Parkinsonfonden (-)
Parkinson Research Foundation (-)
Skåne University Hospital Foundation (-)
The Swedish federal goverment under the ALF agreement (-)
- License Information
-
More Information
Article History
Received: 6 December 2019
Accepted: 4 February 2020
First Online: 13 February 2020
Ethics approval and consent to participate
: All participants gave written informed consent to participate in the study. The study was approved by the regional ethical committee of Lund, Sweden.
: Not applicable.
: OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen, Roche, and Fujirebio. KB has served as a consultant or at advisory boards for Alzheon, Axon, CogRx, Biogen, Novartis, and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ has served at scientific advisory boards for Roche Diagnostics, Samumed, CogRx, and Wave, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KM, GB, SJ, SS, EP, ES, and UA declare that they have no competing interests.
